Sahajanand Medical Technologies Limited (SMT), based in Mumbai, India, has achieved regulatory approval from Health Canada for its Supraflex Cruz sirolimus-eluting coronary stent system. This marks a significant milestone for the company, as it enters the North American market with a product that has received a Class IV medical device license from Health Canada's Medical Devices Directorate. The Supraflex Cruz stent system, part of a family of products, is designed to assist in coronary interventions, offering advanced treatment options for patients with heart conditions. The approval confirms that the device meets stringent Canadian health and safety regulations, paving the way for its launch and distribution within Canada and potentially other North American territories. This development reflects the growing demand for innovative medical technologies in Canada, aiming to improve patient outcomes in cardiovascular care.
Analyzed Canadian Outlets (2)
1 headline · wire copies grouped